Pharmacogenomics market seen reaching $15.98 billion by 2030

The pharmacogenomics market is projected to grow from $9.84 billion in 2025 to $10.85 billion in 2026, fueled by chronic disease prevalence, genomic research and wider use of personalized medicine. The Business Research Company says North America leads now, while Asia-Pacific is expected to be the fastest-growing region through 2030.

Why it matters: - Pharmacogenomics is shaping how doctors choose drugs and doses based on a patient’s genetic profile. - The market’s growth points to wider use of personalized medicine in cancer, cardiology, asthma, Alzheimer’s disease and other chronic conditions. - The shift could improve drug effectiveness and reduce safety risks tied to one-size-fits-all prescribing.

What happened: - The Business Research Company published a new pharmacogenomics market report on Aug. 24, 2026. - The report sizes the market at $9.84 billion in 2025 and $10.85 billion in 2026. - The report projects the market will reach $15.98 billion by 2030. - The forecast implies a 10.3% CAGR from 2025 to 2026 and a 10.2% CAGR from 2026 to 2030. - The company also offered a free sample report and the full market report.

The details: - Growth in 2025-2026 is tied to genomic research, targeted therapy development, chronic disease prevalence, sequencing technology and wider access to genetic testing. - The forecast period is driven by precision medicine investment, AI-based genomic analysis, expanded oncology and cardiology use, personalized drug development and better bioinformatics tools. - The report highlights several trends: broader adoption of personalized medicine, genetic testing in drug selection, more use of pharmacogenomic data in clinical workflows, growth in companion diagnostics and stronger focus on precision therapeutics. - Pharmacogenomics studies how genetic differences affect responses to medication. - The goal is to help healthcare providers choose more effective drugs and doses for individual patients. - The approach is being applied to cardiovascular disease, Alzheimer’s disease, cancer and asthma. - The report defines a pharmacogenomics marker as the delivery of precise medical treatment suited to individuals or specific patient groups. - The Business Research Company says the report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis, future trend analysis and updated graphics and tables.

Between the lines: - Chronic disease growth is doing much of the heavy lifting for demand. - International Diabetes Federation data in the report shows 589 million adults ages 20 to 79 lived with diabetes in 2024, and that figure is projected to hit 853 million by 2050. - Most future diabetes growth is expected in low- and middle-income countries, which expands the addressable need for more tailored drug therapy. - North America held the largest market share in 2025 because of advanced healthcare infrastructure and heavy research activity. - Asia-Pacific is expected to be the fastest-growing region as healthcare spending rises and personalized medicine awareness spreads. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - The market is expected to keep expanding as precision medicine moves deeper into routine care. - Companion diagnostics, clinical workflow integration and AI-driven genomic tools are likely to shape the next phase of growth. - Regional momentum will likely stay strongest in North America and Asia-Pacific, but adoption is broadening globally.

The bottom line: - Pharmacogenomics is moving from a niche research area toward a larger commercial market built on personalized treatment, chronic disease management and genomic data.